Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Category Archives: Follow-On Biologics
“Obamacare” Survives – Including Path to Generic Biologicals
Biotech patent attorneys rejoice – no matter if you represent generic companies or NDA holders, the 5-4 decision of the Supreme Court upholding the “individual mandate” – not under the commerce clause, but as an appropriate use of Congress’ power to … Continue reading
Posted in Follow-On Biologics
Tagged generic biologicals, intellectual property, ip, Obamacare, Patent Law, patents, Supreme Court, Warren Woessner
Leave a comment
Legal Challenge To “ObamaCare” Threatens Generic Biologicals
What should not be lost on pharma/biotech patent attorneys or their clients, amidst all the attention given to the Supreme Court’s review of the “Patient Protection and Affordable Health Care Act” – public law 111-48, is that it contains the … Continue reading
Posted in Follow-On Biologics
Tagged biotechnology law, FDA, Hatch-Waxman, Supreme Court, Warren Woessner
1 Comment
Regulatory Framework For Follow-On Biologics In Health Care Bill
In the early evening of March 25, 2010, the House voted, finalizing the budget reconciliation package earlier passed by the Senate, that contained some relatively minor amendments to the version of the Senate Bill that the House passed in the … Continue reading